Exact Sciences (EXAS) Q2 results: Revenues: $199.9M (+94.3%).
Net Loss: ($38.4M) (-5.5%); Loss Per Share: ($0.30) (unch).
Cologuard test volume: 415K (+93%); average revenue/test: $483; average cost/test: $123.
2019 guidance: Revenue: $800M – 810M from $725M – 740M.
Shares are down 7% premarket.
Previously: EXACT Sciences EPS beats by $0.26, beats on revenue (July 29)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.